Lariocidin - Novel Lasso Peptide Antibiotic / Articles

Introduction

Lariocidin (abbreviated as LAR) is a naturally occurring lasso peptide antibiotic discovered in 2025 by researchers at McMaster University (Canada) from a soil sample collected in a backyard in Hamilton, Ontario. It represents the first lasso peptide reported to inhibit protein synthesis in bacteria through direct interaction with the ribosome. Lariocidin exhibits broad-spectrum activity against both Gram-positive and Gram-negative bacteria, including drug-resistant strains, and demonstrates a low propensity for generating spontaneous resistance. Its unique mechanism of action, favorable safety profile, and potent in vivo efficacy position lariocidin as a promising lead compound for the development of a new class of antibiotics to address the critical threat of antimicrobial resistance.

Chemical Structure and Sources

Lariocidin is a lasso peptide—a class of ribosomally synthesized and post-translationally modified peptides (RiPPs) characterized by a unique threaded structure resembling a lasso. The molecule features a macrolactam ring formed by an isopeptide bond between the N-terminal amino group and a side-chain carboxyl group, through which the C-terminal tail is threaded and trapped by steric hindrance. This knotted conformation confers exceptional thermal and proteolytic stability.

CAS Number: 2694805-94-0
Compound class: Lasso peptide (RiPP)
Producer organism: Paenibacillus sp. M2
Source: Soil sample
Derivative: Lariocidin B (LAR-B) – an internally cyclized derivative with a "double-lasso" structure

Lariocidin is produced by Paenibacillus sp. M2 through a dedicated biosynthetic gene cluster (lrc BGC). Heterologous expression in hosts such as Streptomyces lividans has been successfully used to produce lariocidin, paving the way for scalable production for further studies.

Physical and Chemical Properties

Lariocidin exhibits the following key physicochemical characteristics:

Appearance: White to off-white crystalline powder
Solubility: Soluble in polar organic solvents (DMSO, methanol); limited water solubility
Stability: High stability due to the lasso peptide threaded structure; resistant to proteolytic degradation
Charge: Strong positive charge, which contributes to its interaction with the negatively charged bacterial ribosome
Purity: ≥98 % (HPLC) for research-grade material

The lasso topology provides exceptional stability against thermal and enzymatic degradation, a critical advantage for therapeutic development.

Mechanism of Action

Lariocidin exhibits a novel mechanism of action that distinguishes it from all existing antibiotics:

Ribosome Targeting: Lariocidin binds directly to the bacterial ribosome—the cell's protein synthesis machinery—at a unique site on the small 30S ribosomal subunit. This binding site is distinct from those of other ribosome-targeting antibiotics, explaining the lack of cross-resistance.

Inhibition of Protein Synthesis: By binding to the ribosome, lariocidin interferes with protein synthesis, inhibiting the bacterium's ability to grow and survive. The compound effectively blocks the translation process, halting the production of essential proteins required for bacterial proliferation.

Broad-Spectrum Activity: Lariocidin demonstrates potent activity against a wide range of clinically relevant pathogens, including both Gram-positive and Gram-negative bacteria. In a mouse model of Acinetobacter baumannii infection, lariocidin showed potent in vivo efficacy.

Low Resistance Propensity: Lariocidin is unaffected by common resistance mechanisms and exhibits a low propensity for generating spontaneous resistance. This is attributed to its unique binding site on the ribosome, which is not targeted by existing antibiotics.

Preclinical Profile

Initial preclinical data have demonstrated a favorable therapeutic window:

Human cell toxicity: No observed cytotoxicity in human cell assays
In vivo efficacy: Potent activity in a mouse model of Acinetobacter baumannii infection
Resistance: Low propensity for generating spontaneous resistance
Selectivity: Specific targeting of bacterial ribosomes without affecting human ribosomes

Applications and Research Potential

Lariocidin represents a promising new class of antibiotics with the potential to address the critical threat of antimicrobial resistance:

Infectious Disease Research: Lariocidin is used as a research tool to study ribosome function and protein synthesis inhibition.
Antibiotic Development: As a lead compound, lariocidin provides a valuable new scaffold for the development of next-generation antibiotics.
Drug-Resistant Infections: Its activity against drug-resistant pathogens, including carbapenem-resistant Acinetobacter baumannii and other "superbugs," makes it a promising candidate for treating difficult-to-treat infections.
Structural Biology: The unique lasso peptide structure and its binding mode to the ribosome offer opportunities for structural studies and rational drug design.

Safety and Toxicology

Lariocidin is intended for research use and is not yet approved for human therapeutic applications:

Cytotoxicity: No observed toxicity to human cells in preclinical assays
Selectivity: Specifically targets bacterial ribosomes without affecting human ribosomes
In vivo safety: Favorable therapeutic window observed in animal models
Handling: Standard laboratory safety practices should be observed. Avoid inhalation, ingestion, and skin or eye contact.

Personal protective equipment (PPE) is recommended when handling lariocidin: gloves, safety goggles, and a lab coat. Work should be conducted in a well-ventilated area or chemical fume hood.

Storage and Handling

To maintain product integrity and ensure safe use:

Temperature: Store powder at –20 °C for long-term stability.
Protection: Protect from light and moisture.
Solubility: Prepare stock solutions in DMSO or methanol; dilute in appropriate buffers for biological assays.
Incompatibilities: Avoid contact with strong oxidizing agents.
Shelf life: Typically 12–24 months when stored in properly sealed containers under recommended conditions.
Spills: Collect mechanically; dispose of as hazardous waste according to local regulations.

Conclusion

Lariocidin (CAS 2694805-94-0) represents a landmark discovery in the field of antimicrobial research. As the first lasso peptide antibiotic shown to inhibit bacterial protein synthesis through a unique interaction with the ribosome, it offers a novel mechanism of action that circumvents existing resistance pathways. Its broad-spectrum activity, low resistance propensity, and favorable preclinical safety profile position it as a promising lead compound for the development of a new class of antibiotics. The discovery of lariocidin underscores the continued importance of exploring natural products for novel therapeutic agents and provides a valuable new scaffold for addressing the critical global threat of antimicrobial resistance. Further research into its pharmacokinetics, optimization, and clinical development will determine its ultimate therapeutic potential.